Workflow
葡萄糖酸钙
icon
Search documents
新赣江:关于公司部分生产线复产的公告
Zheng Quan Ri Bao· 2025-09-01 13:38
Core Viewpoint - The company announced a phased production control for its calcium gluconate and zinc gluconate production lines to reduce operational risks and enhance operational efficiency, with production resuming in September 2025 [2] Group 1 - The company implemented a phased production control for calcium gluconate and zinc gluconate production lines starting in July 2025 [2] - The production line for ferrous gluconate resumed operations on August 15, 2025 [2] - The production lines for calcium gluconate and zinc gluconate resumed operations on September 1, 2025 [2]
新赣江(873167) - 投资者关系活动记录表
2025-05-15 12:20
Group 1: Investor Relations Activity - The company held an earnings briefing on May 13, 2025, via an online platform [3] - Attendees included the general manager, financial director, and other key personnel [3] Group 2: Key Financial Information - In 2024, the company invested a total of 8,797,852.61 yuan in R&D, accounting for 5.72% of operating revenue [5] - The company's operating revenue for 2024 was 153,763,382.65 yuan, representing a year-on-year decline of 28.97% [6] Group 3: Future Plans and Strategies - The company aims to enhance R&D and production capabilities, diversify product offerings, and strengthen core competitiveness to boost investor confidence [5] - A cash dividend of 1 yuan per 10 shares (including tax) is planned for 2024, with no stock bonus or capital reserve conversion [5]
科伦药业(002422):一季度业绩承压 全年季度环比望迎改善
Xin Lang Cai Jing· 2025-05-05 08:37
Core Viewpoint - The company reported mixed financial results for 2024 and Q1 2025, with a slight increase in annual revenue but a significant decline in quarterly performance due to high base effects from the previous year [1][2]. Financial Performance - In 2024, the company achieved operating revenue of 21.812 billion yuan, a year-on-year increase of 1.67%, and a net profit attributable to shareholders of 2.936 billion yuan, up 19.53% [1]. - For Q1 2025, the company reported operating revenue of 4.390 billion yuan, a year-on-year decrease of 29.42%, and a net profit of 584 million yuan, down 43.07% [2]. Profitability Metrics - The overall gross margin for 2024 was 51.69%, a decrease of 0.74 percentage points year-on-year, while the expense ratio was 32.27%, down 3.95 percentage points [3]. - In Q1 2025, the gross margin dropped to 48.67%, a decline of 7.17 percentage points year-on-year, with the expense ratio slightly increasing to 32.38% [3]. Business Segments - The infusion business generated sales of 8.912 billion yuan in 2024, a decrease of 11.85%, with sales volume of 4.347 billion bottles/bags, down 0.70% [4]. - Non-infusion drug sales increased by 5.41% to 4.169 billion yuan, driven by strong performance in the plastic water needle business [4]. - The antibiotic intermediates and raw materials segment achieved revenue of 5.856 billion yuan, a year-on-year increase of 20.90%, benefiting from increased market demand [4]. Innovation and Pipeline - The company launched its innovative drug, Lukanosatuzumab (佳泰莱), in November 2024, marking the beginning of a new era in innovative drug commercialization [5]. - Ongoing clinical trials for various ADC therapies are being conducted in collaboration with Merck, targeting multiple cancer types [5][6]. Future Projections - Revenue projections for 2025 to 2027 are estimated at 21.9 billion, 23.36 billion, and 23.98 billion yuan, with corresponding net profits of 3.02 billion, 3.35 billion, and 3.41 billion yuan [7]. - The company is expected to maintain a valuation of 19X for 2025 and 17X for 2026 and 2027 [7]. Investment Rating - The investment rating is maintained at "Buy" based on the company's growth potential and ongoing innovation efforts [8].
新赣江:向不特定合格投资者公开发行股票并在北京证券交易所上市招股说明书
2023-01-19 09:36
江西省吉安市吉州区云章路 36 号 江西新赣江药业股份有限公司 江西新赣江药业股份有限公司招股说明书 证券简称: 新赣江 证券代码: 873167 保荐人(主承销商) (浙江省杭州市西湖区天目山路 198 号财通双冠大厦西楼) 本次股票发行后拟在北京证券交易所上市,该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业,上市公司具有经营风险高、业绩不稳定、退市风险高等特点,投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素,审 慎作出投资决定。 中国证监会和北京证券交易所对本次发行所作的任何决定或意见,均不表明 其对注册申请文件及所披露信息的真实性、准确性、完整性作出保证,也不表明 其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或者保证。 任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定,股票依法发行后,发行人经营与收益的变化,由发 行人自行负责;投资者自主判断发行人的投资价值,自主作出投资决策,自行承 担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 声明 发行人及全体董事、监事、高级管理人员 ...
新赣江:招股说明书(注册稿)
2023-01-09 23:12
证券简称: 新赣江 证券代码: 873167 本次股票发行后拟在北京证券交易所上市,该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业,上市公司具有经营风险高、业绩不稳定、退市风险高等特点,投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素,审 慎作出投资决定。 保荐人(主承销商) (浙江省杭州市西湖区天目山路 198 号财通双冠大厦西楼) 中国证监会和北京证券交易所对本次发行所作的任何决定或意见,均不表明 其对注册申请文件及所披露信息的真实性、准确性、完整性作出保证,也不表明 其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或者保证。 任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定,股票依法发行后,发行人经营与收益的变化,由发 行人自行负责;投资者自主判断发行人的投资价值,自主作出投资决策,自行承 担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 声明 江西省吉安市吉州区云章路 36 号 江西新赣江药业股份有限公司 江西新赣江药业股份有限公司招股说明书(申报稿) 本公司的发行申请尚未经中国 ...